Table 1.

Patient characteristics.

Demographic	All patients	AI (%)	Fulvestrant (%)
	n = 280	n = 209 (74.64)	n = 69 (24.64)
Age at CDK start, years
<50	51	42	9
≥50	228	167	59
ECOG at CDK start
0	144	110	34
1	107	76	29
2	16	12	4
3	2	2	0
Sex
Female	275	204	69
Male	5	5	0
Race/ethnicity
European	242	185	55
Asian	3	2	1
African American	25	15	10
Hispanic & Latino	3	1	2
Other	2	2	0
Menopause status at CDK start
Pre & Peri	49	43	6
Post	222	160	60
Male	5	5	0
Metastatic status
Visceral	133	92	40
Non-visceral	147	117	29
Metastatic status at presentation
De novo	91	81	9
Recurrent	189	128	60
Number of metastatic sites
1	124	92	32
2	86	61	23
≥3	56	45	11
Prior endocrine therapy
Yes	183	118	63
No	97	91	6
Prior chemotherapy
Yes	144	98	46
No	136	111	23

Table showing various demographic characteristics for the patients included in the study.

AI aromatase inhibitor.